New
HealthMore in Health→
GSK Acquires Nuvalent for $10.6B to Boost Targeted Cancer Drug Pipeline
GSK is acquiring Nuvalent, a biotech focused on targeted cancer therapies, for $10.6 billion, adding promising lung cancer drugs to its pipeline.
Key Takeaways
- GSK to acquire Nuvalent for $10.6 billion.
- Nuvalent develops targeted cancer drugs zidesamtinib and neladalkib.
DE
DT Editorial Team··via statnews.com